Sanfilippo Syndrome
New Sanfilippo syndrome research, summarized each month in plain language.
2026 so far: In the months covered (February 2026 to September 2026), patient-derived cell studies narrowed already-approved drug candidates for MPS IIIA and showed very different responses between two MPS IIIB cell lines, while other reports highlighted diagnostic gaps and the need for follow-up testing. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Drug repurposing in neurons. Cell-based screening moved from broad ideas to specific shortlists to test next.
- Different drug responses. Lab screening suggested early drug leads may depend on the individual patient.
- Whole-body involvement. Case reports added detail on complications beyond the brain, but only in a few individuals.
- Getting the right subtype. More genetic-first diagnoses were reported, along with clearer examples of where testing can miss important findings.
- Imaging markers. Imaging studies put numbers on retina patterns and described brain changes in a small number of cases.
New
September 2026
- Approved drug shortlist. Several approved drugs reduced MPS IIIA-like changes in lab neurons.
- Nerve signaling measures. Tests also measured changes in how nerve cells signal.
- Cell toxicity signal. Some screened drugs damaged or killed cells in the dish.
August 2026
- Diagnosis by exome. Whole-exome sequencing helped diagnose when enzyme testing was unavailable.
- Subtype labels. Genetic results identified MPS IIIA and MPS IIIC subtypes.
- Brain imaging findings. Brain scans showed changes consistent with ongoing brain involvement.
July 2026
- Approved drug signals. Some approved drugs improved a lysosome-related lab signal.
- Patient-to-patient differences. The same drugs did not help another patient's cells.
- Dye-based measure. The result was a dye signal, not stored-sugar levels.
June 2026
- NAGLU gene range. Many different NAGLU gene changes appeared in type B.
- New NAGLU changes. Two NAGLU gene changes were first reported in one group.
- Vision-led findings. HGSNAT changes were linked to vision loss without clear Sanfilippo.
May 2026
- Genetic testing when labs are unavailable. In one family, gene testing identified an MPS IIIA (Sanfilippo type A) variant when other laboratory tests were not available.
- Similar symptoms, different MPS type. In a second family with similar symptoms, testing pointed to a different mucopolysaccharidosis type caused by a different gene.
- Organ involvement beyond the brain. One autopsy report in advanced MPS IIIA described storage-related changes in multiple organs, not only in the brain.
- Computer-based variant impact estimate. A computational study predicted that one NAGLU variant (I154R) could be damaging to the enzyme based on modeling.
April 2026
- Network imbalance over time. In lab-grown brain cell networks, the balance between “go” (excitatory) and “stop” (inhibitory) signaling shifted as the networks matured.
- Stronger excitatory signaling. Patient-derived networks showed signs of overactive excitatory connections.
- Spermidine in models. Spermidine improved movement in flies, but in a short mouse study it showed limited changes in brain measures.
March 2026
- Central retina changes. Eye imaging often showed changes in the outer retina near the center of vision.
- Optic nerve layer often normal. The retinal layer linked to the optic nerve often looked normal on imaging.
- Adult confirmation of MPS IIIC. Sanfilippo type IIIC (MPS IIIC) was confirmed in adults using genetic and laboratory testing.
February 2026
- Confirming the subtype. Broad genetic testing did not detect every kind of gene change, and enzyme testing plus targeted genetic follow-up helped confirm Sanfilippo type IIIB in one family.
- Very early trehalose results. In two siblings, six trehalose injections were reported with no measurable improvement, which is a limited observation rather than clear evidence of benefit.
- Acute metabolic acidosis case. One person with Sanfilippo type A was reported with an episode of acute metabolic acidosis, but a single case cannot show how common or predictable this is.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Sanfilippo syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).